The Predictive Ability of C-Peptide in Distinguishing Type 1 Diabetes From Type 2 Diabetes: A Systematic Review and Meta-Analysis

被引:10
作者
Iqbal, Sajid [1 ,2 ,4 ]
Abu Jayyab, Abdulrahim [2 ]
Alrashdi, Ayah Mohammad [2 ]
Reverte-Villarroya, Silvia [1 ,3 ]
机构
[1] Univ Rovira Virgili, Nursing Dept, Campus Terres Ebre,Ave Remolins, Tarragona, Spain
[2] Liwa Coll Technol, Dept Hlth & Med Sci, Abu Dhabi, U Arab Emirates
[3] Catalan Inst Hlth, Hosp Tortosa Verge Cinta, Pere Virgili Inst, Carretera Esplanetes, Tarragona, Spain
[4] Univ Rovira Virgili, Campus Terres Ebre,Ave Remolins 13-15, Tortosa 43500, Tarragona, Spain
关键词
beta-cell function; Predictive; diabetes; Type mellitus; predictive ability of C -peptide; Beta; type; 1; 2; C-peptide; EUROPEAN ASSOCIATION; INSULIN THERAPY; CLASSIFICATION; MELLITUS; AUTOIMMUNITY; MANAGEMENT; ADA; AGE;
D O I
10.1016/j.eprac.2023.01.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This systematic review and meta-analysis aimed to investigate the predictive ability of plasma connecting peptide (C-peptide) levels in discriminating type 1 diabetes (T1D) from type 2 diabetes (T2D) and to inform evidence-based guidelines in diabetes classification. Methods: We conducted a holistic review and meta-analysis using PubMed, MEDLINE, EMBASE, and Scopus. The citations were screened from 1942 to 2021. The quality criteria and the preferred reporting items for systematic reviews and meta-analysis checklist were applied. The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42022355088). Results: A total of 23,658 abstracts were screened and 46 full texts reviewed. Of the 46 articles screened, 12 articles were included for the meta-analysis. Included studies varied by race, age, time, and proportion of individuals. The main outcome measure in all studies was C-peptide levels. A significant association was reported between C-peptide levels and the classification and diagnosis of diabetes. Furthermore, lower concentrations and the cutoff of <0.20 nmol/L for fasting or random plasma C-peptide was indicative of T1D. In addition, this meta-analysis revealed the predictive ability of C-peptide levels in discriminating T1D from T2D. Results were consistent using both fixedand random-effect models. The I2 value (98.8%) affirmed the variability in effect estimates was due to heterogeneity rather than sampling error among all selected studies. Conclusion: Plasma C-peptide levels are highly associated and predictive of the accurate classification and diagnosis of diabetes types. A plasma C-peptide cutoff of <0.20 mmol/L is indicative of T1D and of & GE;0.30 mmol/L in the fasting or random state is indicative of T2D. & COPY; 2023 AACE. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 48 条
[1]   Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients [J].
Ahn, CW ;
Kim, HS ;
Nam, JH ;
Song, YD ;
Lim, SK ;
Kim, KR ;
Lee, HC ;
Huh, KB .
DIABETIC MEDICINE, 2002, 19 (03) :227-233
[5]  
[Anonymous], 2015, Oesophago-gastric cancer: Assessment and management in adults
[6]  
[Anonymous], 2019, 2019 SURVEILLANCE DI
[7]  
[Anonymous], 2011, Diabetes Care, DOI [DOI 10.2337/DC11-9998, 10.2337/dc11-9998]
[8]   Current State of Diabetes Mellitus Prevalence, Awareness, Treatment, and Control in Latin America: Challenges and Innovative Solutions to Improve Health Outcomes Across the Continent [J].
Aviles-Santa, M. Larissa ;
Monroig-Rivera, Alberto ;
Soto-Soto, Alvin ;
Lindberg, Nangel M. .
CURRENT DIABETES REPORTS, 2020, 20 (11)
[9]   Fasting C-peptide and Related Parameters Characterizing Insulin Secretory Capacity for Correctly Classifying Diabetes Type and for Predicting Insulin Requirement in Patients with Type 2 Diabetes [J].
Becht, F. S. ;
Walther, K. ;
Martin, E. ;
Nauck, M. A. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2016, 124 (03) :148-156
[10]   Random C-peptide in the classification of diabetes [J].
Berger, B ;
Stenström, G ;
Sundkvist, G .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2000, 60 (08) :687-693